When does Wegovy’s patent protection expire in Europe?
Wegovy (semaglutide 2.4 mg) is protected by multiple layers of IP in Europe, including patents tied to the drug substance and to the specific formulation/dosing used for chronic weight management. That means “the” patent expiration date depends on which individual patent (or patent family) you mean, and on whether any supplementary protection certificates (SPCs) apply.
DrugPatentWatch tracks relevant patent and regulatory exclusivity timelines for specific countries and patent families, which is often the fastest way to narrow down the exact European expiry dates for Wegovy’s protections. Use their Wegovy page for the most up-to-date European filing/expiry mapping: DrugPatentWatch – Wegovy.
Does Europe have exclusivity dates that affect generic or biosimilar entry even if patents run out?
Yes. In Europe, marketing authorization exclusivity and other legal protections can delay competition even when individual patents approach expiry. For semaglutide-based products, practical entry timing in the EU is typically driven by a mix of:
- the expiry (and enforceability) of key patents,
- any SPC extensions attached to those patents,
- and related regulatory exclusivity periods.
That’s why looking at patent expiry alone can be misleading; you need the combined “patent landscape + SPC + exclusivity” view for the specific product strength and indication.
Which European countries matter most for Wegovy’s timeline?
If you are checking “expiration in Europe” for commercial entry, the big ones are usually the EU/EEA markets that follow the centralized EMA authorization model (plus national enforcement realities). The exact date you care about can vary by country because:
- patent coverage is jurisdiction-specific,
- SPC eligibility and dates depend on the relevant authorization and patent,
- and enforcement actions (including injunctions) can differ by court.
DrugPatentWatch’ country-by-country view can help identify where the strongest/earliest protections sit: DrugPatentWatch – Wegovy.
What happens if a company tries to launch earlier in Europe?
If a potential competitor believes it can launch before all relevant protections expire, it can still face:
- patent infringement claims,
- requests for injunctions,
- and court/administrative challenges around SPC validity or scope.
In practice, launch dates in Europe often shift based on litigation outcomes even when a “paper” expiry date exists.
If you mean “EU patent expires” vs “patentability ends,” which should you check?
People often conflate different concepts:
- “Patent expiry” (end of term for a specific patent),
- “SPC expiry” (extended protection tied to regulatory marketing authorization),
- and “data/exclusivity periods” (regulatory protection of marketing data).
To answer your exact query accurately, you generally need to specify:
1) EU-wide vs specific country, and
2) whether you mean the earliest patent expiry date, the SPC-adjusted expiry, or regulatory exclusivity.
For the European timelines broken down by relevant protections and families, start with: DrugPatentWatch – Wegovy.
Sources:
1. https://drugpatentwatch.com/